{"product_id":"vetoquinol-pestle-analysis","title":"Vetoquinol PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic pressures, and evolving tech trends are shaping Vetoquinol’s strategy and market risks in our concise PESTLE snapshot; this analysis highlights regulatory, environmental, and social factors that matter now. Purchase the full PESTLE to access detailed, actionable insights and scenario-ready recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary drug approval regimes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory pathways like EMA (centralized assessment baseline 210 days), FDA CVM (often multi-year review timelines) and Brazil MAPA (commonly \u0026gt;12 months) directly shape Vetoquinol time-to-market and trial design for animal therapeutics. Harmonization gaps between these regions force separate dossiers and trials, raising launch complexity and per-product costs. Political shifts tightening residue, antimicrobial or welfare rules can disqualify products, so Vetoquinol must sequence filings and tailor evidence packages by jurisdiction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntimicrobial stewardship policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAntimicrobial stewardship policies — driven by WHO's 2019 estimate of 1.27 million AMR-attributable deaths — are prompting governments to restrict indications, dosing and over-the-counter access, compressing sales in key segments. EMA\/ESVAC reports a 34% decline in veterinary antimicrobial sales 2011–2020, while procurement and surveillance programs increasingly favor vaccines and diagnostics, making proactive stewardship positioning critical to win tenders and policy goodwill.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural subsidy and trade policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFarm support schemes, notably the EU CAP framework (€387 billion for 2021–27), shape herd sizes and producers’ capacity to invest in animal health. Tariffs, non‑tariff barriers and export bans alter disease exposure and demand for therapeutics within global agricultural trade (~$1.9 trillion, FAO 2022). Political tensions can disrupt supply of actives and packaging, so scenario planning is used to balance exposure between livestock and companion animal markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health and zoonosis preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational preparedness agendas fund surveillance, vaccination and rapid-response tools; WHO estimates 60% of human infectious diseases are zoonotic and 75% of emerging pathogens originate from animals. WHO R\u0026amp;D Blueprint and national transboundary disease priority lists drive stockpiles and accelerated regulatory reviews. Political attention after outbreaks often reallocates budgets toward prevention; WHO estimates a US$4.5 billion annual funding gap to meet IHR capacities, creating openings for Vetoquinol to align portfolios with high-priority pathogens to access national and multilateral funding.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003esurveillance funding tied to national plans\u003c\/li\u003e\n\u003cli\u003epriority pathogen lists drive stockpiles and fast-track reviews\u003c\/li\u003e\n\u003cli\u003e60% zoonotic \/ 75% emerging pathogen origin\u003c\/li\u003e\n\u003cli\u003eUS$4.5 billion annual IHR funding gap\u003c\/li\u003e\n\u003cli\u003ealignment with high-priority pathogens unlocks funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpgeopolitical supply risk: sanctions conflicts and export controls can constrain apis logistics lanes noting that roughly of global active pharmaceutical ingredients originate in china india reports through energy policy shocks raised european industrial costs intermittently since increasing manufacturing margin volatility. governments accelerated reshoring incentives pushing firms to reassess footprints diversified sourcing regional plants reduce exposure.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPIs concentration ~60% China\/India\u003c\/li\u003e\n\u003cli\u003eEnergy-driven margin volatility since 2022\u003c\/li\u003e\n\u003cli\u003e2024 reshoring incentives influencing footprint\u003c\/li\u003e\n\u003cli\u003eDiversified sourcing + regional plants mitigate risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pgeopolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory split, AMR risk, supply-chain reshoring and US$4.5bn funding gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory divergence (EMA centralized ~210 days, FDA CVM multi‑year, MAPA \u0026gt;12 months) and AMR policy (WHO 1.27M deaths; EMA veterinary antimicrobial sales -34% 2011–2020) force separate dossiers, tailored indications and sequenced launches. EU CAP (€387bn 2021–27), API concentration (~60% China\/India) and 2024 reshoring incentives shift footprint and pricing risk; US$4.5bn IHR funding gap creates funding opportunities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMA review\u003c\/td\u003e\n\u003ctd\u003e~210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMR deaths (WHO)\u003c\/td\u003e\n\u003ctd\u003e1.27M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVet antimicrobial decline\u003c\/td\u003e\n\u003ctd\u003e-34% (2011–2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU CAP\u003c\/td\u003e\n\u003ctd\u003e€387bn (2021–27)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI sourcing\u003c\/td\u003e\n\u003ctd\u003e~60% China\/India\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIHR funding gap\u003c\/td\u003e\n\u003ctd\u003eUS$4.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Vetoquinol across Political, Economic, Social, Technological, Environmental and Legal dimensions, with data-backed trends, region-specific regulatory insights and forward-looking scenarios to help executives, investors and strategists identify risks, opportunities and clear actions for planning and funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Vetoquinol's full PESTLE into a clean, shareable summary that eases strategic discussions and can be dropped into presentations for quick stakeholder alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock cycle and commodity prices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFeed represents roughly 60% of livestock production costs, and feed, milk and meat prices swung up to ±30% y\/y in 2023–24, constraining farmer spending on health products and shifting purchases toward ROI-positive therapeutics. High input costs tend to cut discretionary treatments while outbreaks (eg. avian\/ASF spikes) have temporarily raised demand by an estimated 25–60%. Vetoquinol’s portfolio should balance preventive solutions with acute-care, high-margin offerings to stabilize revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion animal premiumization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising pet ownership—about 70% of US households per the 2023–24 APPA survey—and growing insurance uptake (roughly 3–4% penetration in the US) underpin demand for higher‑value therapies and diagnostics; the global pet care market is forecast near USD 269 billion by 2025. Macroeconomic slowdowns push buyers toward generics and smaller pack sizes. Urbanization (locked at ~56% globally) expands small‑animal clinics and retail channels. Pricing ladders enable capture across income tiers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMulti-currency revenue and cost bases expose Vetoquinol margins to FX swings, with emerging-market currencies having weakened roughly 10%–15% versus the euro in recent years, squeezing distributor liquidity and customer affordability. Depreciations in key EM markets have reduced local purchasing power and delayed payments. Active hedging programs and natural offsets cut P\u0026amp;L noise, while increased local invoicing and cost localization have stabilized cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and input costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAPI, excipient and packaging inflation (about 8–12% in 2024 across animal-health supply chains) compressed gross margins, while wage and energy rises added roughly 5–7% to conversion costs at plants; price increases often lag due to annual list cycles and multi-year tender terms, so productivity programs and SKU optimization have been used to protect ~200–300 bps of profitability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPI\/excipient\/packaging: +8–12% (2024)\u003c\/li\u003e\n\u003cli\u003eConversion costs: +5–7% (wages, energy)\u003c\/li\u003e\n\u003cli\u003ePricing lag: annual lists\/tenders\u003c\/li\u003e\n\u003cli\u003eMitigation: productivity, SKU rationalization (~200–300 bps)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChannel consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpchannel consolidation: veterinary group purchasing and corporate clinics now exert strong bargaining power with corporate-owned accounting for about of u.s. companion-animal visits in pressuring margins trade terms.\u003e\n\u003cpdistributors and e-commerce pet-medicine sales in yoy growth push harder on pricing consolidation enables data-driven formularies favoring proven outcomes while real-world evidence plus bundled services support premium retention.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate share ~35% (2024)\u003c\/li\u003e\n\u003cli\u003eOnline pet med sales ~$4.8B (2024), ~20% YoY\u003c\/li\u003e\n\u003cli\u003eFormularies driven by outcomes and RWE\u003c\/li\u003e\n\u003cli\u003eService bundles defend pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdistributors\u003e\u003c\/pchannel\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory split, AMR risk, supply-chain reshoring and US$4.5bn funding gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFeed ~60% of livestock costs; feed\/milk\/meat swung ±30% y\/y in 2023–24, cutting discretionary spend and favoring ROI-positive therapeutics. Pet ownership ~70% US (2023–24) and pet market ~USD 269B by 2025 boost premium demand, while macro slowdowns shift buyers to generics\/smaller packs. API\/excipient +8–12% (2024), conversion +5–7%; EM FX -10–15% vs EUR squeezed margins; online pet med ~$4.8B (2024), corporate clinics ~35% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFeed share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice volatility (2023–24)\u003c\/td\u003e\n\u003ctd\u003e±30% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/packaging inflation (2024)\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConversion costs\u003c\/td\u003e\n\u003ctd\u003e+5–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEM FX vs EUR\u003c\/td\u003e\n\u003ctd\u003e-10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePet market\u003c\/td\u003e\n\u003ctd\u003e~USD 269B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline pet meds\u003c\/td\u003e\n\u003ctd\u003e~USD 4.8B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate clinics\u003c\/td\u003e\n\u003ctd\u003e~35% (US, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eVetoquinol PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Vetoquinol PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. This file is the final version with no placeholders or teasers. The layout, content, and structure visible are identical to the downloadable product. After payment you’ll instantly get this same professional file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675943911801,"sku":"vetoquinol-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/vetoquinol-pestle-analysis.png?v=1755810788","url":"https:\/\/portersfiveforce.com\/products\/vetoquinol-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}